Abstract: A magnetic body detecting device constituting a magnet portion for magnetizing a magnetic body from a magnet main body portion, and a correcting portion which is disposed in front of magnet main body portion to correct a magnetic field generated by magnet main body portion, wherein the correcting portion is configured to form a specific position N having a desired magnetic field intensity by canceling out the magnetic field generated by magnet main body portion, and to adjust the magnetic field gradient at a magnetic field null point N of the magnetic field generated by magnet portion by causing magnet main body portion to be separated from a front end portion of magnet portion in accordance with the magnetic field gradient in the correcting portion, and wherein a magnetic sensor is disposed at the magnetic field null point N formed in the front end portion of the magnet portion.

Abstract: A magnetic body detecting device constituting a magnet portion for magnetizing a magnetic body from a magnet main body portion, and a correcting portion which is disposed in front of magnet main body portion to correct a magnetic field generated by magnet main body portion, wherein the correcting portion is configured to form a specific position N having a desired magnetic field intensity by canceling out the magnetic field generated by magnet main body portion, and to adjust the magnetic field gradient at a magnetic field null point N of the magnetic field generated by magnet portion by causing magnet main body portion to be separated from a front end portion of magnet portion in accordance with the magnetic field gradient in the correcting portion, and wherein a magnetic sensor is disposed at the magnetic field null point N formed in the front end portion of the magnet portion

Abstract: A magnetic fluid detecting device (1) that detects magnetic fluid that has been injected into a living body has a detector (2) that detects magnetic fluid in the body when it is in contact with or adjacent to the body, an output device (3) that outputs the detection results in a prescribed output form, a controller (4) that controls the output device (3) based on the detected value inputted from the detector (2), and a power supply module (5) that supplies power to the detector (2), output device (3) and controller (4), using a battery B as the power source. The detector (2), output device (3), controller (4) and power supply module (5) are integrated to allow holding with one hand.

Abstract: Disclosed is a cisplatin-resistance marker for determining whether ovarian tumor cells of interest are resistant to cisplatin. The cisplatin-resistance marker of the present invention includes a polynucleotide having any one of the base sequences of SEQ ID NOs. 1 to 11 and can be used in a detection method involving the following steps (1) to (3) to determine whether ovarian tumor cells of interest are resistant to cisplatin: (1) hybridizing RNA prepared from a biological sample from a subject, or a complementary polynucleotide transcribed from the RNA, with the cisplatin-resistance marker; (2) quantifying the RNA from the biological sample, or the complementary polynucleotide transcribed from the RNA, that has hybridized with the cisplatin-resistance marker, using the cisplatin-resistance marker as an index; and (3) determining whether the biological sample is a cisplatin-resistant ovarian tumor based on the results of the quantification.

Abstract: This invention relates to a method for producing non-human animal mutants, characterized in that the method comprises irradiating a male germ cell with heavy ion beams and selecting a mutated animal from animals, which are produced from an egg and the irradiated male germ cell, and their generations. According to the invention, non-human animal mutants with various phenotypes or morphological characters can efficiently be produced.

Abstract: An individual information management system to manage individual data comprises a data carrier which is attached to said individual, and which stores data relating to said individual, and

Abstract: A cancer metastasis inhibitor which comprises as an active ingredient an anti-tenascin monoclonal antibody which neutralizes the physiological functions of a tenascin by binding to the FGF-like domain and other domains of the tenascin and prevents the metastasis of cancer to other organs such as the lungs.

Abstract: Embryonic stem cell lines C-6 and C-2, Cr/A-3, DB1, and B6-26 have been derived from the inbred mice strains C3H/HeN, BALB/c, DBA/1J, and C57BL/6N, respectively. The embryonic stem cells are alkaline phosphatase positive and express a C3H specific antigen. The embryonic stem cell lines are useful in genetic research and the production of knockout mice.

Abstract: Embryonic stem cells derived from an inbred mouse strain selected from the group consisting of C3H/HeN, C57BL/6N, DBA/1J, and BALB/c strains, for example, C-2 cell having the accession number FERM BP-5933 and C-6 cell having the accession number FERM BP-5934 are disclosed. The embryonic stem cells of the present invention are derived from genetically complete inbred strains, and therefore, they are extremely useful for close genetic research.

Abstract: A novel monoclonal antibody of IgG1/.kappa. subclass, characterized in that it recognizes antigens specifically present in mouse inbred strains consisting of DBA/1, CE/J, SM/J, IQI, PL/J, SWM/Ms, RIIIS/J, RFM/MsNrs and C3H and its congenic mouse strains thereof, wherein one of said antigens has a molecular weight of 66,000 and the other has a molecular weight of 68,000 and said antigens are present in the mitochondria of C3H mouse strain.The present invention also provides a hybridoma cell line which produces the above monoclonal antibody, a method for identifying the origin of a cell derived from a mouse, and a reagent for identifying the origin of a cell derived from a mouse.